Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5,706 Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care
Substance Use Disorders · HIV · Depression
Primary: Change in Mental Health and Substance Use Screening Rates — 2008; 2379 Participants
N/A N=81 Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders
Posttraumatic Stress Disorders · Combat Disorders · Alcohol Dependence
Primary: Change in Post-traumatic Stress Disorder Symptomatology — -51.2; -35.9; -22.3; -10.9 score on a scale
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
Phase 1 N=101 Woebot for Substance Use Disorders
Substance Use Disorders
Primary: Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) From Baseline to Post-treatment at 8 Weeks — -9.3 score on a scale
Phase 1 N=180 W-SUDs for COVID-19
Substance Use Disorders · Alcohol Use Disorder
Primary: Change in Number of Substance Use Occasions in the Past 30 Days From Baseline to Post-treatment at 8 Weeks — -9.1; -4.7 occasions
Phase 4 N=105 Bupropion for ADHD in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
N/A N=667 LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
Phase 1 N=73 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorders
Primary: Alcohol Craving — 2.89; 3.08 scores on a scale
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
Phase 2 N=258 The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -11.3; -11.2; -13.6; -12.9 occasions
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
N/A N=97 Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Drug Use · Alcohol Use · Congestive Heart Failure
Primary: Change in Substance Use Rates From Baseline — 51.37; 51.38; 35.53; 26.65 Days of Substance Use
N/A N=122 Adolescents With Substance Use Disorders Transitioníng From Residential Treatment to the Community
Substance Use · Adolescent Behavior
Primary: Change in Proportion of Days Used Outside of Controlled Environment — .27; .35; .35; .32 proportion of days used — p=.12
Phase 2 N=63 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorder · Stress Disorders, Post-Traumatic · Anxiety Disorders
Primary: Change in Craving to Use Alcohol Rating (Visual Analog Scale) — 0.076; -0.928 score on a scale
N/A N=47 Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults With Substance Use Disorders
Substance Use Disorders · Depression · Anxiety
Primary: Acceptability of Adding UP Group Intervention to TAU — 28.0 units on a scale
Phase 3 N=303 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
N/A N=20 Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -0.6; -7.2; -3.9; -6.7 occasions
Early Phase 1 N=131 Managing Chronic Pain in Veterans With Substance Use Disorders
Chronic Pain
Primary: Pain Intensity, as Measured by Average Pain Within the Last Week (NRS-1) — 5.82; 6.47 units on a scale — p=<0.05
N/A N=59 Behavioral Treatment of Adolescent Substance Use
Substance Use Disorders
Primary: Any Cannabis Abstinence — 13; 18 participants
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
N/A N=117 SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)
Substance Use Disorders · Posttraumatic Stress Disorder
Primary: Severity of Alcohol Use (ASI Alcohol Composite Scores) — .259; .225; .169; .152 units on a scale — p=> .05
Phase 4 N=24 Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
Substance Use Disorders · Bipolar Disorder · Mood Disorders
Primary: Change in Timeline Followback of Substance Use (TLFB) — 2.3; 3.3 Days
N/A N=200 Women's Treatment and Early Recovery
Substance-related Disorders
Primary: Treatment Completion — 43; 31 Number of women — p=<0.05
Phase 3 N=28 The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial
Sleep Disturbance · Craving · Cortisol; Hypersecretion
Primary: Change in Total Sleep Time as Measured by Actigraphy and Sleep Logs Relative to Baseline Over the Course of 7 Days of Treatment With Suvorexant in Substance Use Disorder…
N/A N=368 Feasibility and Validation of a Standard Phenotyping Assessment Battery
Opioid-use Disorder · Cocaine Use Disorder · Marijuana Use Disorder
Primary: Retention — 4; 27; 10; 21 Participants
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens